Medical Oncologist,MD
Brazil
Joined July 2017
- Tweets2.5K
- Following1.4K
- Followers361
- Likes14.5K
Vânia Godo retweeted
Craig Mello was awarded the Nobel Prize after discovering a process called RNA interference, which can regulate gene expression by silencing selected genes, or rendering them inactive. This plays an important regulatory role within a genome.
Read more: bit.ly/3eM8UBh
ALT Craig Mello in his lab looking into a microscope.
Vânia Godo retweeted
🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice!
From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming.
🔥 My Top 15 to Watch:
1. INTerpath-001 | Melanoma
2. SAFFRON | EGFR+ NSCLC
3. Krascendo 1 | KRAS G12C NSCLC
4. DeLLphi-305 | ES-SCLC
5. HARMONi-GI1 | Biliary
6. VOLGA | Bladder
7. DASL-HiCaP | Prostate
8. NATALEE | Breast
9. TRIO-US B-12 TALENT | Breast
10. ENERGIZE | Bladder
11. CLARITY-Gastric 01 | Gastric
12. KEYNOTE-C93 | Endometrial
13. KEYNOTE-B49 | Breast
14. LITESPARK-011 | RCC
15. SigVie-002 | NSCLC
📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care?
Not every positive trial is practice-changing.
👨⚕️ Oncologists, which trial are you watching most closely?
#ESMO26 #Oncology #CancerResearch
@ASCO @oncoalert @myesmo @esmo_open
Vânia Godo retweeted
The FDA approved 22 new drugs in Q3 2026.
Key oncology approvals:
- Daraxonrasib
- Gedatolisib
- Camizestrant
- Zidesamtinib
- Lirafugratinib
Daraxonrasib leads commercial forecasts, with projected annual sales of $6.6 billion by 2032.
nature.com/articles/d41573-0…
Vânia Godo retweeted
What were the highlights from EASD 2026? Our congress hub will keep you up to date with the top stories and latest evidence in diabetes research.
Vânia Godo retweeted
Honey bees inject venom with a two-stroke stinger.
Learn more: scim.ag/4yXrVF5 @NewsfromScience
Vânia Godo retweeted
Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist, compared to a standard combination approach.
Recently published in @NEJM, these findings come from the phase 3 evERA Breast Cancer study, led by Principal Investigator @elmayermd. Read more: bit.ly/4jGjOYA
Vânia Godo retweeted
Prepare for meaningful peer-to-peer conversations at ESMO 2026 using this free, CME-accredited webcast, led by Dr. Larisa J. Geskin.
Vânia Godo retweeted
Beyond genes and hotspots: Protein-informed interpretation of cancer mutations dlvr.it/TVx3Sr
Vânia Godo retweeted
We are all mosaics with our cells accumulating somatic mutations as we age. Now that is getting fully comprehensively quantified @CellCellPress
cell.com/cell/fulltext/S0092…
Vânia Godo retweeted
🗞️Our October issue is live!✨Read about lipid remodelling and lifespan regulation; how age-related T-cell accumulation drives myelopoiesis; senescent B-cells in rheumatoid arthritis risk; exercise-derived vesicles promote cartilage health & much more! nature.com/nataging/volumes/…
Vânia Godo retweeted
Most popular number in research might be p < 0.05
Probably also one of the most misunderstood!
Consider two studies:
→ Study A finds a tiny effect with p = 0.001.
→ Study B finds a potentially important effect, but the confidence interval is wide and includes no effect.
Which deserves more attention?
The answer depends on the research question, the uncertainty, and what difference the effect would make in practice.
A p-value alone cannot settle that.
This is a simple visual explaining what p-values and confidence intervals actually tell us.
Worth keeping nearby when reading or writing research papers.
----------------
𝐅𝐢𝐧𝐝 𝐢𝐭 𝐮𝐬𝐞𝐟𝐮𝐥?
Retweet (& like)
Follow @RaziaAliani to get more useful Research content (no clickbait stuff!) in your feed.
Want FREE tips on using AI in research?
↳ Join 18K+ researchers here ⬇️
🔗 newsletter.razia-aliani.com
Vânia Godo retweeted
The immune system as the explanation for why the Shingles vaccine has shown protection vs dementia in 4 natural experiments
pnas.org/doi/10.1073/pnas.26…
Vânia Godo retweeted
🗳️ I encourage @UICC voting members to support @glopes, for President-elect. His extensive global oncology experience across Asia, Brazil, and Miami, combined with his commitment to listening, collaboration, and measurable progress, makes him an outstanding leader to advance cancer control worldwide. 🌎🎗️ #UICC #CancerControl #GlobalOnc
🎥 youtu.be/FehR9Ai_kWg
Voting for UICC’s next President-elect is open.
I am honored to stand as a candidate and grateful for the opportunity to have served on the @UICC Board and chaired the ATOM Coalition.
These experiences, together with our work advancing lung cancer policy through IASLC, have reinforced three convictions:
Listen to members. Strengthen institutions. Turn commitments into measurable progress.
Our achievements belong to the many organisations, advocates, clinicians, policymakers, and partners working together across countries.
If elected, I will bring that same commitment to listening, partnership, and delivery to UICC’s next chapter.
I would be grateful for the support of UICC’s voting members.
Together, we can accomplish more.
#UICC #CancerControl #GlobalOncology
youtu.be/FehR9Ai_kWg
Vânia Godo retweeted
The personalized neonantigen vaccines to treat cancer, already shown to work in malignant melanoma, and in trials of pancreatic cancer, glioblastoma, renal cell cancer, and triple-negative breast cancer.....now ovarian cancer. Results from a Phase 1 trial
nature.com/articles/s41591-0…
Vânia Godo retweeted
New Online! Atomic, structural and molecular insights into GPCR ligand binding and signalling dlvr.it/TVvMLQ
Vânia Godo retweeted
What if immune cells could be reprogrammed to fight cancer directly inside the body, instead of in a lab?
A new @NatureBiotech study from MIT used lipid nanoparticles to deliver CAR mRNA directly to natural killer (NK) cells.
Up to 80% of NK cells were reprogrammed in mice using an NKG2D-targeted particle. Targeting NKG2A, an inhibitory checkpoint, both delivered the mRNA and relieved an inhibitory brake, leading to complete tumor regression in most treated mice in a melanoma model, with no recurrence through day 100.
CAR expression was temporary, and repeat dosing may be needed. Still preclinical. But a cell therapy delivered from a vial instead of manufactured in a lab could transform access to cancer treatment.
Vânia Godo retweeted
New online! Mosquito-based malaria control through genetic, microbial and immunological innovations dlvr.it/TVv94h
